Novavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022
11/01/2022 - 04:02 PM
GAITHERSBURG, Md. Nov. 1, 2022 Tuesday, November 8, 2022 , following the close of U.S. financial markets. Details of the event and replay are as follows:
Conference call details:
Date:
November 8, 2022
Time:
4:30 p.m. U.S. Eastern Daylight Time (EDT)
Dial-in number:
833) 974-2381 (Domestic) or (412) 317-5774 (International)
Webcast:
ir.novavax.com/events
Participants will be prompted to request to join the Novavax, Inc. call. To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
Replay details:
Date:
Available starting at 7:30 p.m. EDT, November 8, 2022 until 11:59 p.m. U.S. EDT, November 15, 2022
Dial-in number:
(877) 344-7529 (Domestic) or (412) 317-0088 (International)
Passcode:
3408655
Webcast:
ir.novavax.com/events , until February 8, 2023
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. The Novavax COVID-19 vaccine has received authorization from multiple regulatory authorities globally, including the U.S. Food and Drug Administration, the European Commission, and the WHO. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional populations and indications such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating its CIC vaccine candidate in a Phase 1/2 clinical trial, its quadrivalent influenza investigational vaccine candidate, and an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent format Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on LinkedIn .
Contacts: Investors Erika Schultz | 240-268-2022 ir@novavax.com
Media Ali Chartan or Giovanna Chandler | 202-709-5563 media@novavax.com
https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-and-operational-highlights-on-november-8-2022-301665315.html
SOURCE Novavax, Inc.
NVAX Rankings
#5166 Ranked by Stock Gains
NVAX Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Gaithersburg
About NVAX
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
